Loading
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Regular session
$37.77
−$2.93 · -7.20%
Regular session · ET · Market data may be delayed.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Day range
Current $37.77
52-week range
Current $37.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
57
Mixed
Risk
40
Moderate Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Day range
Current $37.77
52-week range
Current $37.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 109.79M USD | 90.4M USD | 82.71M USD | 64.36M USD | 48.04M USD |
| Cost of goods sold | 12.45M USD | 8.88M USD | 9.36M USD | 7.65M USD | 5.16M USD |
| Gross profit | 97.34M USD | 81.52M USD | 73.35M USD | 56.7M USD | 42.89M USD |
| Research and development | 67.11M USD | 57.15M USD | 45.61M USD | 52.91M USD | 47.64M USD |
| Selling, general, and administrative | 155.1M USD | — | 93.27M USD | 82.84M USD | — |
| Operating expenses | 222.2M USD | 178.3M USD | 138.89M USD | 135.74M USD | 135.18M USD |
| Interest income | 5.97M USD | 8.9M USD | 2.64M USD | 938K USD | 365K USD |
| Interest expense | 33.85M USD | 12.52M USD | 14.72M USD | 8.44M USD | 17.44M USD |
| Depreciation and amortization | 2.41M USD | 1.19M USD | 1.71M USD | 1.82M USD | 1.77M USD |
| Operating income | −124.86M USD | −96.78M USD | −65.54M USD | −79.04M USD | −92.29M USD |
| Net income | −153.49M USD | −126.87M USD | −102.24M USD | −109.78M USD | −110.82M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM45.54M0.06%78.56B USD0.19%$276.96-0.27%
iShares Russell 2000 Growth ETFIWO13.99M0.10%14.25B USD0.24%$352.55-0.79%
iShares Biotechnology ETFIBB12.78M0.12%10.4B USD0.44%$200.01-1.64%
Vanguard Russell 2000 ETFVTWO10.55M0.06%18B USD0.06%$111.87-0.31%
Fidelity Enhanced Small Cap ETFFESM8.6M0.13%6.41B USD0.28%$45.115-0.23%
State Street SPDR Portfolio Developed World ex-US ETFSPDW7.74M0.02%41.32B USD0.03%$49.585-0.73%
iShares Micro-Cap ETFIWC5.46M0.41%1.33B USD0.60%$182.24-0.61%
Vanguard Health Care ETFVHT5.1M0.02%22B USD0.09%$313.02-0.72%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMState Street SPDR Portfolio Developed World ex-US ETFSPDWiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
